Hospira HSP

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns

      Headlines

      Thu, 26 Jun 2014

      BBB- 2020 5.50% $108.88 3.73% 188 Hospira HSP BBB- 2023 5.80% $111.56 4.26 ..... 50 basis points of additional tightening. Hospira HSP "> HSP (rating: BBB-, narrow moat) Hospira 's bonds could outperform its peers, as

    2. New Morningstar Analyst Report for Hospira Inc

      Stock Reports

      Tue, 24 Jun 2014

      consent decree. A 2014 patent expiration on Hospira 's branded anesthetic Precedex and commencement ..... the company's profitability.Sales of Hospira 's medical devices should remain depressed ..... removed and hospital spending improves. Hospira is one of the first companies to successfully

    3. New Morningstar Analyst Report for Amgen Inc

      Stock Reports

      Fri, 6 Jun 2014

      dialysis drug payments), potential branded competition (Mircera as early as 2014), and biosimilar launches (including Hospira in 2016). For neutropenia drugs Neupogen and Neulasta, we see sales declining from $5.8 billion in 2013 to $4.4 billion

    4. Top 10 Purchases and Sales from Our Ultimate Stock-Pickers

      Headlines

      Tue, 3 Jun 2014

      this quarter: three that worked out well (Cimarex Energy, Concho Resources and Crane) and three that didn’t (Encana, Hospira and Quest Diagnostics)... In the case of Encana and Quest Diagnostics, fundamental underperformance caused us to reexamine

    5. PJP PowerShares Dynamic Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Mon, 5 May 2014

      strong valuations paid by strategic buyers and public investors for units spun out of Big Pharma firms, including Abbott ABT ( Hospira HSP, OTC brands, in vitro diagnostics division, point-of-care diagnostics division), Pfizer (Zoetis ZTS), and Bristol

    6. IHE iShares US Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Mon, 5 May 2014

      strong valuations paid by strategic buyers and public investors for units spun out of Big Pharma firms, including Abbott ABT ( Hospira HSP, OTC brands, in vitro diagnostics division, point-of-care diagnostics division), Pfizer (Zoetis ZTS), and Bristol

    7. XPH SPDR S&P Pharmaceuticals ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Mon, 5 May 2014

      strong valuations paid by strategic buyers and public investors for units spun out of big pharma firms, including Abbott ABT ( Hospira HSP, OTC brands, in vitro diagnostics division, point-of-care diagnostics division), Pfizer (Zoetis ZTS), and Bristol

    8. Hospira Posts Encouraging First-Quarter Results, but Generic Precedex Should Slow Momentum

      Commentary

      Wed, 30 Apr 2014

      Hospira posted first-quarter results that slightly ..... allowances during last year's device issues, Hospira realized 7.5% revenue growth when excluding ..... to shift our $44 fair value estimate as Hospira continues to face considerable challenges

    9. Hospira HSP Q1 2014 Earnings Call Transcript

      Headlines

      Wed, 30 Apr 2014

      Welcome to Hospira 's First Quarter 2014 Conference Call ..... conference call and webcast discussing Hospira 's financial results for the first quarter ..... Mike Ball, Chief Executive Officer of Hospira and Tom Werner, Senior Vice President

    10. Oakmark Equity and Income Fund Letter to Shareholders

      Headlines

      Tue, 8 Apr 2014

      establish a meaningful position. Hospira was a longtime holding of the Fund ..... Laboratories, which spun-off Hospira ten years ago. Over the past few years ..... Crane Co. 0%, Encana Corp. 0%, Hospira , Inc . 0%, Abbott Laboratories 0

    « Prev12345Next »
    Content Partners